Read by QxMD icon Read

Merkel carcinoma

(no author information available yet)
No abstract text is available yet for this article.
April 2018: Australian Prescriber
Ioannis Gavvovidis, Matthias Leisegang, Gerald Willimsky, Natalie J Miller, Paul Nghiem, Thomas Blankenstein
PURPOSE: The causative agent of most cases of Merkel cell carcinoma (MCC) has been identified as the Merkel cell polyomavirus (MCV). MCV-encoded T-antigens (Tags) are essential not only for virus-mediated tumorigenesis but also for maintaining MCC cell lines in vitro. MCV Tags are thus an appealing target for viral oncoprotein-directed T cell therapy for MCC. With this study, we aimed to isolate and characterize Tag-specific T cell receptors (TCR) for potential use in gene therapy clinical trials...
April 18, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Juliana Pinho, Diana Montezuma, Paula Monteiro, Mário Dinis-Ribeiro, Pedro Bastos
Merkel cell carcinoma (MCC) is a rare and aggressive primary neuroendocrine tumor of the skin, with a high propensity for local, regional and distant spread1 . However, distant metastasis of MCC to the pancreas are rarely seen. EUS-FNA is an effective tool in the evaluation and differential diagnosis of pancreatic mass lesions3 . Differentiating metastatic pancreatic tumors, especially Merkel cell carcinoma, from primary pancreatic tumor will influence clinical management and therapeutic strategies2 . This article is protected by copyright...
April 17, 2018: Cytopathology: Official Journal of the British Society for Clinical Cytology
Brian B Hughley, Cecelia E Schmalbach
Cutaneous malignancy of the head and neck affects a large proportion of elderly patients. The severity ranges from small, easily treatable lesions to large, invasive, potentially metastatic tumors. Surgical treatment is the primary treatment of most skin cancers; however, geriatric patients are more likely to have multiple comorbidities that increase the risk of surgery. Multiple treatment modalities exist, including surgical, radiation, and medical therapy. Recommendations and treatment options for basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, and melanoma are outlined and reviewed...
May 2018: Clinics in Geriatric Medicine
Rachael Davenport, Sarah Brennand, Michelle Sy Goh, Saurabh Prakash, Alvin H Chong
No abstract text is available yet for this article.
April 16, 2018: Australasian Journal of Dermatology
Pavandeep Gill, Christopher Naugler, Marie S Abi Daoud
Ber-EP4 has been the traditional immunostain used for the detection of basaloid skin tumors. Recently, MOC-31 has shown be superior to Ber-EP4 in the detection of basosquamous basal cell carcinoma (BCC) and many centers are now using both Ber-EP4 and MOC-31 antibodies together to detect these lesions. The objective of this study was to compare the utility of using both Ber-EP4 and MOC-31 immunostains in the detection of basaloid skin tumors and to better characterize the previously unknown staining properties of MOC-31 in cutaneous lesions...
April 7, 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
Cameron M Callaghan, Rumpa Amornmarn
Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin initially believed to arise from the Merkel cells. In the community setting a general radiation oncologist may only encounter this pathology in a handful of cases over the course of their career. Due to the low incidence of this malignancy, few prospective randomized controlled trials have ever been conducted and therefore guidelines are based on relatively lower levels of evidence upon which the clinical recommendations are made. We discuss the case of a female in her 90s presenting with a classic MCC primary lesion, as well as satellite lesions proximal to both the primary and the draining regional lymph nodes with no evidence of nodal involvement...
April 12, 2018: Radiation Oncology Journal
Jocelyn Joseph, Chrystia Zobniw, Jennifer Davis, Jaime Anderson, Van Anh Trinh
OBJECTIVE: To summarize the clinical development of avelumab and its clinical relevance in metastatic Merkel cell carcinoma (MCC). DATA SOURCES: An English-language literature search using PubMed was performed using the terms avelumab, anti-PD-1, anti-PD-L1, and MCC from January of 1950 to March 2018. Data were also obtained from package inserts, meeting abstracts, and clinical registries. STUDY SELECTION/DATA EXTRACTION: All relevant published articles of avelumab were reviewed...
April 1, 2018: Annals of Pharmacotherapy
Sebastian Fischer, Philippe A Federspil, Katharina Kriegsmann, Thomas Longerich, Mark Kriegsmann
No abstract text is available yet for this article.
March 1, 2018: International Journal of Surgical Pathology
Rami N Al-Rohil, Denái R Milton, Priyadharsini Nagarajan, Jonathan L Curry, Laurence Feldmeyer, Carlos A Torres-Cabala, Doina Ivan, Victor G Prieto, Michael T Tetzlaff, Phyu P Aung
Primary cutaneous Merkel cell carcinoma (MCC) is an aggressive neuroendocrine malignancy in which lymphovascular invasion (LVI) correlates with more aggressive phenotype. The prognostic significance of LVI detected by D2-40 immunohistochemistry (IHC) in MCC remains controversial. We aimed to determine how LVI detected by D2-40 IHC compares with LVI detected by hematoxylin-eosin (H&E) staining in predicting MCC metastasis. Clinical and histopathologic features of MCCs diagnosed and treated during 2002-2015 were assembled and included 58 MCC tumors from 58 patients...
March 27, 2018: Human Pathology
Thibault Kervarrec, Mahtab Samimi, Pauline Gaboriaud, Tarik Gheit, Agnès Beby-Defaux, Roland Houben, David Schrama, Gaëlle Fromont, Massimo Tommasino, Yannick Le Corre, Eva Hainaut-Wierzbicka, Francois Aubin, Guido Bens, Hervé Maillard, Adeline Furudoï, Patrick Michenet, Antoine Touzé, Serge Guyétant
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The main etiological agent is Merkel cell polyomavirus (MCPyV), detected in 80% of cases. About 5% of cases, called combined MCC, feature an admixture of neuroendocrine and non-neuroendocrine tumor cells. Reports of the presence or absence of MCPyV in combined MCC are conflicting, most favoring the absence, which suggests that combined MCC might have independent etiological factors and pathogenesis. These discrepancies might occur with the use of different virus identification assays, with different sensitivities...
March 28, 2018: Virchows Archiv: An International Journal of Pathology
J P Foy, F Kolb, E Routier, A Cavalcanti, J Lumbroso, G Tomasic, C Mateus, S Temam, C Robert, A Moya-Plana
Non-melanoma skin cancer (NMSC), the most common malignancy worldwide, includes Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC). Although CSCC are often associated with favorable outcomes, one to ten percent of cases develop regional metastatic disease, lowering significantly the survival rate. In contrast, MCC is aggressive with high rate of loco-regional disease (around 50%), resulting in a poor prognosis. This article is protected by copyright. All rights reserved.
March 24, 2018: Clinical Otolaryngology
Oleksandr Trofymenko, Nathalie C Zeitouni, Drew Jb Kurtzman
BACKGROUND: The stage of disease at initial diagnosis and the use of radiation therapy (RT) are important determinants of survival in patients with Merkel cell carcinoma (MCC). OBJECTIVE: To define factors that are associated with advanced stage MCC at the time of initial diagnosis and the use of RT. METHODS: Cross-sectional, retrospective analysis of MCC patients registered in the National Cancer Database during 2004-2013. RESULTS: A total of 11,917 patients were identified...
March 21, 2018: Journal of the American Academy of Dermatology
Renata Ferrarotto, Robert Cardnell, Shirley Su, Lixia Diao, A Karina Eterovic, Victor Prieto, William H Morrisson, Jing Wang, Merrill S Kies, Bonnie S Glisson, Lauren Averett Byers, Diana Bell
BACKGROUND: Patients with metastatic Merkel cell carcinoma are treated similarly to small cell lung cancer (SCLC). Poly ADP-ribose polymerase-1 (PARP1) is overexpressed in SCLC and response to PARP inhibitors have been reported in patients with SCLC. Our study explores PARP as a therapeutic target in Merkel cell carcinoma. METHODS: We evaluated PARP1 expression and Merkel cell polyomavirus (MCPyV) in 19 patients with Merkel cell carcinoma. Target exome-sequencing was performed in 14 samples...
March 23, 2018: Head & Neck
Nicholas Turnbull, Waseem Ghumra, Vivek Mudaliar, Josefa Vella, D Scott A Sanders, Saleem Taibjee, Richard Carr
Tricholemmoma, a benign follicular neoplasm with outer root sheath differentiation, typically comprises clear or pale cells, and when multiple is pathognomic of Cowden's syndrome. The tumor is probably underrecognized and in basaloid examples can be difficult to distinguish from basal cell carcinoma (BCC). We studied 55 tricholemmomas (including 15 basaloid cases) and compared immunohistochemical profile with nodular BCC from our archives. Basaloid and non-basaloid tricholemmomas had similar staining characteristics...
March 21, 2018: American Journal of Dermatopathology
Els van der Meijden, Mariet Feltkamp
Approximately 15-20% of human cancer is related to infection, which renders them potentially preventable by antimicrobial or antiviral therapy. Human polyomaviruses (PyVs) are relevant in this regard, as illustrated by the involvement of Merkel cell polyomavirus (MCPyV) in the development of Merkel cell carcinoma. The polyomavirus Small and Large tumor antigen (ST and LT) have been extensively studied with respect to their role in oncogenesis. Recently it was shown that a number of human PyVs, including MCPyV and the trichodysplasia spinulosa polyomavirus (TSPyV), express additional T-antigens called Middle T (MT) and alternative T (ALT)...
2018: Frontiers in Microbiology
Murthy S Anand, Shantha Krishnamurthy, Suvarna Ravindranath, Jyothi Ranganathan
Merkel cell carcinoma (MCC) is a rare, clinically aggressive neuroendocrine carcinoma of the skin; MCC is 40 times less common as compared to melanoma. The most frequently reported sites have been the head and neck, extremities, and trunk. Potential mimics include malignant melanoma, lymphoma, or metastatic small cell (neuroendocrine) carcinomas. Histopathology of MCC resembles small cell carcinoma both morphologically and on IHC. The possible cell of origin was proposed as the Merkel cell, which functions as a mechanoreceptor...
January 2018: Indian Journal of Pathology & Microbiology
Vivien Lai, William Cranwell, Rodney Sinclair
Epidermal cancers include keratinocyte cancer, melanocyte cancer, and Merkel cell carcinoma. These cancers account for the vast majority of new cancers diagnosed in Australia, North America, and Europe. Keratinocyte cancer is the most common epidermal cancer and accounts for 7 out of 8 new cancers diagnosed in Australia. Melanoma and Merkel cell carcinoma are less common than keratinocyte carcinoma but are more important causes of mortality in Australia. Keratinocyte cancer has also been demonstrated to be a marker of cancer-prone phenotype...
March 2018: Clinics in Dermatology
Isaac S Chan, Shailender Bhatia, Howard L Kaufman, Evan J Lipson
Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In this review, we discuss the rationale for the use of immune checkpoint inhibition, review current single agent therapies tested in and approved for MCC, and discuss emerging immunotherapeutic options for these patients...
March 23, 2018: Journal for Immunotherapy of Cancer
Sandra P D'Angelo, Jeffery Russell, Céleste Lebbé, Bartosz Chmielowski, Thilo Gambichler, Jean-Jacques Grob, Felix Kiecker, Guilherme Rabinowits, Patrick Terheyden, Isabella Zwiener, Marcis Bajars, Meliessa Hennessy, Howard L Kaufman
Importance: Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated with poor survival outcomes in patients with distant metastatic disease. Results of part A of the JAVELIN Merkel 200 trial (avelumab in patients with Merkel cell carcinoma) showed that avelumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, demonstrated efficacy in second-line or later treatment of patients with metastatic MCC (mMCC). Objective: To evaluate the efficacy and safety of avelumab as first-line treatment for patients with distant mMCC...
March 22, 2018: JAMA Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"